Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574912 · ClinicalTrials.gov registry record · Phase 1
Characteristics of Glargine in Type 2 Diabetics
A Phase 1 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00574912 is a Phase 1 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT00574912, a Phase 1 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The study is to determine the dose response relationship of insulin glargine in type 2 diabetes over a 24-hour period and measuring the differences in glucose production among the differing doses of glargine. Hypothesis: Differing doses of insulin glargine over a 24-hour period in type 2 diabetes will show differing effects on endogenous glucose production, glucose disposal and carbohydrate and lipid flux.
Interventions
- DRUG Placebo
- DRUG Insulin Glargine 0.5 u/kg body wt SC
- DRUG Insulin Glargine 1.0 u/kg body wt SC
- DRUG Insulin Glargine 1.5 u/kg body wt SC
- DRUG Insulin Glargine 2.0 u/kg body wt SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-03 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00574912
The ClinicalTrials.gov registry entry for NCT00574912 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00574912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00574912 about?
NCT00574912 is a clinical study titled "Characteristics of Glargine in Type 2 Diabetics". The study is to determine the dose response relationship of insulin glargine in type 2 diabetes over a 24-hour period and measuring the differences in glucose production among the differing doses of glargine. Hypothesis: Differing doses of insulin glargine over a 24-hour period in type 2 diabetes w...
What is the current status of trial NCT00574912?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-03. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00574912?
The interventions under investigation include: Placebo (DRUG), Insulin Glargine 0.5 u/kg body wt SC (DRUG), Insulin Glargine 1.0 u/kg body wt SC (DRUG), Insulin Glargine 1.5 u/kg body wt SC (DRUG), Insulin Glargine 2.0 u/kg body wt SC (DRUG).
Who is sponsoring clinical trial NCT00574912?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.